ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Gout FocusRheum expanded abstract sample

Gout is a common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. The good news: The etiology of gout is well understood, and effective, inexpensive medications exist to treat it. However, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout. New features are added often, so check back frequently.

Gout expert Lisa Stamp, MBChB, FRACP, PhD, will sort through the research abstracts on gout accepted for presentation at ACR Convergence 2024 to bring you the most important concepts and findings.

FEATURED ARTICLE: AC&R Study Summary: TV & the Public Perception of Gout

 

Reducing Immunogenicity of Pegloticase ... Click here to view abstract videoReducing Immunogenicity of Pegloticase ... Click here to view visual abstract summary

ACR Convergence

Research Roundup: Abstract Data Presented at ACR Convergence 2021

The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…

Research on Diet & Gout

According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout.1 Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in…

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.

Research, Case Reports & More

Gout & Cardiometabolic Co-Morbidities

ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.

Editor's Pick

Calcium Pyrophosphate Deposition Disease: The Great Mimic

CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.

Gout Flares & the NLRP3 Inflammasome

Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as a new treatment option.

SAP-001 Promising for Refractory Gout

Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.

Urate-Lowering Therapy in the Treatment of Patients with Chronic Kidney Disease

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Better Education on Gout

Experts addressed how education and follow-up for patients with gout can improve disease management and highlighted the need for a better construction of gout remission.

Progress in Gout Education & Remission

An ACR Convergence 2024 session will discuss strategies to educate patients about their disease and review the progress toward the concept of remission in gout to better guide physicians.